Most pharmaceutical companies measure their ambition by how quickly they can reach the United States. Torrent Pharmaceuticals, out of Ahmedabad, measured its by something less obvious: how deeply it could embed its brands into the prescribing habits of doctors in India, Brazil, and Germany. Five decades later, the strategy has compounded $560 million into $1.4 billion — and made Torrent the number-one Indian pharmaceutical company in both Brazil and Germany (per company filings).
The insight behind Torrent is deceptively simple: chronic diseases require chronic medication. A patient diagnosed with hypertension at forty will take cardiovascular drugs every day for the rest of their life. A diabetes patient needs anti-diabetic therapy indefinitely. If you can build a brand that a cardiologist trusts enough to prescribe by name — and if that brand is a generic priced for middle-income markets — you have an annuity, not just a product.
Torrent built its domestic business on this insight. Its core therapeutic areas — cardiovascular, central nervous system, gastrointestinal, anti-diabetic, and vitamins & minerals — are all chronic or sub-chronic segments where physicians prescribe by brand and patients stay on therapy for years. By FY 2025, 72% of Torrent’s revenue came from branded generics, and more than 55% of total revenue came from India, where the company ranks seventh in the national pharmaceutical market.
This is not a company that chases blockbusters. Its biggest products — Shelcal, Unienzyme, Nikoran, Ahaglow — are medicines and consumer health brands that sell in steady, compounding volumes, year after year. The unsexy arithmetic of chronic therapy, done well, turns out to be a very good business.
Torrent’s growth story is punctuated by three acquisitions, each of which reshaped the company. In FY 2015, Torrent acquired Elder Pharmaceuticals’ branded formulation business, adding established consumer health and pain management brands to its portfolio and pushing revenue to $560 million. The integration sent revenue surging 43% to $801 million in FY 2016.
In FY 2018, the company acquired Unichem Laboratories’ domestic branded business, absorbing a portfolio of fifty-two products and vaulting Torrent to fifth place in the Indian pharmaceutical market. This was not a deal to gain scale in generic commodities — it was a deal to gain brands, specifically branded generics in chronic therapeutic categories where Torrent already had field-force coverage and physician relationships. The employee count jumped from 11,781 to 14,700 in a single year.
The third move came in FY 2023, when Torrent acquired Curatio Health Care, adding dermatology and cosmo-dermatology products — a new therapeutic lane for a company that had historically focused on cardiology and CNS. With each acquisition, Torrent followed the same logic: buy brands that doctors already trust, in therapeutic areas where patients stay on therapy for years, and integrate them into an existing sales infrastructure.
The most unusual thing about Torrent’s international strategy is where it chose to compete. While most Indian pharmaceutical companies poured resources into the United States — the world’s largest pharmaceutical market — Torrent built its international crown jewels in Brazil and Germany.
In Brazil, Torrent is the number-one Indian pharmaceutical company and ranks fifteenth in the overall market, with 15% annual growth and ten brands exceeding BRL 15 million in sales each. The company focuses on CNS, cardiovascular, and oral anti-diabetic therapies — the same chronic categories it dominates at home. In Germany, Torrent is the fifth-largest generic company and the number-one Indian pharmaceutical company, competing directly with Teva, Sandoz, and Stada in one of Europe’s most sophisticated generics markets.
The US business exists — Torrent ranks eleventh among Indian players, with 135 US FDA drug approvals (all ANDAs) — but it accounts for only 10% of revenue. This is a deliberate allocation, not a failure. Torrent chose to be dominant in three markets rather than marginal in one.
Torrent operates in more than fifty countries, with India contributing 55% of consolidated revenue in FY 2025. The international portfolio is anchored by three pillars: Brazil and Germany (10% each), the United States (10%), and a growing roster of emerging markets including Mexico and the Philippines. The company maintains manufacturing facilities in India and Brazil, with eight plants supporting its global supply chain.
Torrent operates eight manufacturing facilities, with plants in India and Brazil. Five of these carry US FDA registration. The company holds 135 US FDA drug approvals (all ANDAs) and 74 Indian Patent Office grants, weighted toward formulation and process innovations in cardiovascular, CNS, and gastrointestinal therapies.
The manufacturing footprint reflects Torrent’s strategic priorities: vertical integration in India for the domestic and emerging-market supply chain, and targeted capacity in Brazil to serve its largest international market with locally manufactured product. This is a company that builds capacity where it sells, not where it is cheapest to produce.
Sources: Torrent Pharmaceuticals Annual Reports FY2014–15 through FY2024–25. US FDA facility registration data. Indian patent office records.